Oslo, 23 October 2023. Lytix Biopharma - Lytix Biopharma AS ("Lytix") (Euronext
Growth Oslo: LYTIX), a clinical stage immuno-oncology company, will release its
third quarter 2023 results on Thursday, November 9. The results will be
presented in a webcast with CEO Øystein Rekdal, CDO Graeme Currie and CFO Gjest
Breistein at 2:30 pm CEST.

The presentation and subsequent Q&A session will be held in English and may be
viewed live by registering here: https://forms.office.com/e/N0xJzSx0Gg

The presentation will be available at www.lytixbiopharma.com in the Investors
section from 08:00 am CET the same day, and a recording of the presentation will
after the presentation be made available.

***

For more information, please contact: 
Gjest Breistein, CFO: gjest.breistein@lytixbiopharma.com
Ole Peter Nordby, Head of IR & Communications Manager:
ole.peter.nordby@lytixbiopharma.com

***

Lytix in brief: 
Based in Oslo, Norway, Lytix Biopharma is a clinical stage immuno-oncology
company developing novel cancer immunotherapies, an area within cancer therapy
that is aimed at activating the patient's immune system to fight cancer. The
Company's technology is based on pioneering research in "host defense peptides"
- nature's first line of defense towards foreign pathogens. Lytix Biopharma's
lead product, LTX-315, is a first-in-class molecule representing a new and
superior therapeutic principle to kill cancer cells and boost anti-cancer
immunity, with the potential to be the ideal combination partner with other
types of immunotherapy. LTX-315 targets cancer cells and disintegrates their
cell membranes, causing immunogenic cell death and release of a patient's tumor
specific antigens.  This mode of action allows cytotoxic T cells to recognize,
infiltrate, and attack cancer cells. The Company was listed on Euronext Growth
in Oslo in June 2021, following a private placement covered by investors
including PBM Capital, a US based, healthcare-focused investment firm.